Your electronic data capture (EDC) budget rarely breaks on the number in the initial quote. It breaks eighteen months later, when a new hire triggers a per-seat fee nobody budgeted for, a protocol amendment needs a vendor programmer billed by the hour, or a second study on the same platform resets a price you thought was locked in. Viedoc's EDC software runs on unlimited user seats and transparent, study-based licensing, with study go-live typically completed in as little as 8 weeks and a modular structure your finance team can actually model against. This comparison reviews five EDC platforms for cost-conscious biotech sponsors across pricing transparency, total cost of ownership, no-code configuration, and compliance credentials.
You're the one who has to explain to the board why the EDC line item grew faster than your trial portfolio did. Vendor quotes rarely show the full picture until you're mid-contract: professional services hours for every amendment, per-seat fees that punish headcount growth, and validation costs that surface right when your QA team needs sign-off fastest. A platform that looks affordable at the proposal stage can still blow your total cost of ownership open by year two.
Enterprise platforms built for large Phase III programs carry pricing structures designed around big pharma budgets, not growth-stage sponsors funding a handful of concurrent trials. Medidata's build cycles can stretch close to 90 days once professional services get involved, and every one of those days adds cost before your study enrolls a patient. The five platforms below are judged on what actually drives your total spend: pricing transparency, no-code configuration that keeps services hours down, and scalability that doesn't force a renegotiation every time your pipeline grows.
Best EDC solutions: quick comparison
| Platform | Product / module | Overview |
|---|---|---|
| Viedoc | EDC software | No-code eClinical platform with unlimited user seats, transparent study-based licensing, and study go-live typically in as little as 8 weeks across 8,000+ completed studies. |
| Medidata | Rave EDC | Enterprise EDC used across more than 30,000 studies, with a Rave Lite tier aimed at Phase I, Phase IV, and post-market studies on a lighter-weight pricing structure. |
| Veeva | Vault EDC | Cloud-based EDC within the Veeva Vault Clinical Suite, built for sponsors standardizing EDC, CTMS, and eTMF on a single connected platform. |
| Castor EDC | EDC / CDMS | Cloud-native EDC with a low-code eCRF builder, reporting build times of 3-4 weeks for low-complexity studies across more than 19,000 studies. |
| Medrio | CDMS/EDC | No-code, cloud-based EDC and clinical data management platform used from early phase through post-market, with a code-free base for fast study copy. |
These five EDC platforms represent the most evaluated options for cost-conscious biotech sponsors, reviewed across pricing transparency, total cost of ownership, configuration speed, and compliance.
1. Viedoc
Viedoc's EDC software is licensed on a transparent, study-based model with unlimited user seats built in, so a growing team never triggers a new fee tier mid-trial. Study builds typically go live in as little as 8 weeks, and the same no-code Designer that builds the study handles mid-study changes, cutting vendor-billable hours that usually pad an amendment invoice. Viedoc has powered more than 8,000 global studies with a 100% FDA inspection pass rate.
For the sponsor holding the budget, the advantage is cost predictability rather than a lower sticker price. Viedoc's licensing scales by study size, complexity, and duration rather than by headcount, so hiring a new data manager doesn't change your contract. The same platform carries a study from Phase I through later phases without a re-platforming decision or a fresh negotiation at each transition.
Viedoc is ISO 27001 and SOC 2 Type II certified and supports FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, and HIPAA, hosted on Microsoft Azure with 99.99% uptime. The Viedoc Inspection Readiness Packet (VIRP) is included in every license at no extra cost. Support runs 24/7 across Viedoc's global offices, included in the license rather than billed separately.
"My experience with Viedoc has been excellent. The database is very customizable and has been able to meet the needs of each of our studies. Customer Support has been excellent with quick turnarounds and response time." – Amanda M., Sr. Clinical Program Manager
Verified proof points:
- Pricing: Unlimited user seats; transparent, study-based licensing with no per-user fees
- Build speed: Study go-live typically completed in as little as 8 weeks
- Study scale: 8,000+ completed global studies; 100% FDA inspection pass rate
- Compliance: FDA 21 CFR Part 11, GDPR, EU Annex 11, HIPAA; ISO 27001 and SOC 2 Type II certified
- Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) included in every license
- Support: 24/7 support across global offices, included in the license
2. Medidata
Medidata offers Rave EDC, an electronic data capture system used across more than 30,000 clinical studies. An independent 2025 sponsor benchmarking report named Rave EDC a top-ranked preferred EDC platform. Rave EDC captures and manages site, patient, and lab data across Phase I through Phase IV trials and connects to a wider suite of Medidata applications, including eConsent, eCOA, and randomization and trial supply management (RTSM). The platform includes AI-assisted configuration tools and supports single sign-on and electronic health record data entry through Rave Companion. For early-phase and post-market studies, Medidata also offers Rave Lite, a pre-configured, lighter-weight version of Rave built for Phase I, Phase IV, and device feasibility studies on a flexible pricing structure.
3. Veeva
Veeva offers Vault EDC as part of the Veeva Vault Clinical Suite, which combines EDC with clinical trial management (CTMS), electronic trial master file (eTMF), and study start-up applications on a single cloud platform. Vault EDC uses drag-and-drop, point-and-click study design rather than custom coding, and Veeva reports a median study build time of roughly seven weeks across its customer base, with amendments handled without data migration or downtime. The platform includes targeted source data verification, protocol deviation tracking, and role-based interfaces for site monitoring and medical review. Vault EDC data flows to other Veeva Vault applications, giving sponsors a single connected data environment once they adopt the broader Vault suite, and serves sponsors across all trial phases with particular strength among large and mid-to-large pharma organizations.
4. Castor EDC
Castor EDC is a cloud-native electronic data capture and clinical data management platform built around a low-code eCRF builder that lets study teams configure forms without deep technical expertise. Castor reports deploying low-complexity studies in as little as 3-4 weeks and has supported more than 19,000 studies across sponsors, CROs, academic institutions, and medical device companies. The platform integrates EDC with eConsent, ePRO/eCOA, and real-world data tooling on a single data layer, and supports field-level encryption, two-factor authentication, and audit trails aimed at inspection readiness. Castor also offers Castor Essentials, a streamlined version of the platform built for smaller studies and leaner budgets. Founded in the Netherlands in 2012, Castor serves customers primarily across Europe and the US, with a focus on Phase I, II, and IV trials and real-world evidence studies.
5. Medrio
Medrio provides a cloud-based clinical data management system (CDMS) and EDC platform built around no-code, point-and-click study configuration, positioned as an alternative to platforms that require programmer-led builds. The platform supports online and offline data capture, dynamic reporting, and code-free study copy functionality intended to shorten setup time between similar studies. Medrio's suite extends to ePRO/eCOA, eConsent, and RTSM, and the company reports a 98% customer retention rate. According to Medrio, studies can go live in hours to days using its code-free base, and mid-study changes can be tested before going live to avoid downtime. Medrio has operated since 2005 and serves sponsors and CROs from early phase through post-market studies, including medical device and diagnostics trials.
What to look for in EDC solutions for cost-conscious biotech sponsors
Pricing model transparency, not just the license quote
Most EDC vendors will show you a license fee before you sign. Fewer will show you what triggers a change to that fee once the study is underway, and for a growth-stage sponsor managing a board-approved budget, that gap is where forecasts fail.
Best-in-class pricing is study-based rather than seat-based, with unlimited users built into the license and add-on modules itemized up front rather than negotiated mid-contract. Overlook this and a platform that looked cost-competitive at the proposal stage can end up costing more than the "premium" alternative once headcount and add-ons are factored back in.
Total cost of ownership beyond the license fee
The license is only one line of the bill. Vendor-side programming for every amendment, validation and computer system validation (CSV) support, and training for each new data manager all sit outside the sticker price on programmer-dependent platforms.
Best-in-class platforms include training, maintenance, updates, and CSV support in the standard license rather than billing them separately, so a protocol amendment doesn't generate a services invoice on top of the monthly fee. A platform priced to look affordable on paper can still carry the highest total cost of ownership once these recurring services are added back in.
No-code configuration that keeps services hours down
Programmer-dependent EDC platforms push cost into professional services every time a study changes, and protocols change often between first-in-human work and later-phase trials.
The strongest platforms let your own data management team build and amend studies through a visual, drag-and-drop interface, with no vendor-side coding required for routine changes. For a lean sponsor team, this is often the single biggest lever on total spend across a multi-study portfolio.
Scalability without a renegotiation at every phase transition
A platform that fits a Phase I budget can become the wrong fit, or the wrong price, once a program moves into Phase II or III with more sites and more data volume.
Look for a single platform that scales from early-phase to later-phase trials on the same contract structure, rather than one that requires a new negotiation or a full data migration at each transition. Switching platforms mid-portfolio carries its own validation and training cost, so scalability on the existing contract is itself a cost-avoidance criterion, not just a convenience.
How to choose the right EDC solution for cost-conscious biotech sponsors
Step 1: Define your growth trajectory over the next two to three years
Map how many concurrent studies, new hires, and phase transitions you expect over the platform's likely contract term, not just what your current single study requires.
Step 2: Assess total cost of ownership, not the license quote alone
Ask each vendor what is included in the license versus billed separately: training, CSV support, mid-study amendments, and technical support. The gap between "included" and "extra cost" is usually where the real budget risk sits.
Step 3: Evaluate who builds and amends your studies
Confirm whether your own data managers can configure and amend studies directly, or whether every change routes through a vendor programmer on a billable basis. This distinction affects both speed and recurring cost more than almost any other platform feature.
Step 4: Scrutinize contract terms for phase-transition and scale triggers
Read the pricing schedule for what happens at renewal, at a headcount increase, and at a phase transition. Unlimited seats and study-based, rather than seat-based, pricing removes one of the most common sources of unbudgeted cost.
Step 5: Choose a platform built for sponsor-side cost predictability
Once you've stress-tested the pricing model against total cost of ownership, choose the platform built to keep cost predictable as your portfolio scales, rather than the one with the lowest number on the first quote. Viedoc's transparent, study-based licensing and unlimited user seats are built for exactly this kind of long-range budgeting, and the team can walk you through how the model holds up against your own three-year plan if you book a demo.
Frequently asked questions
What is the best EDC platform for cost-conscious biotech sponsors?
Viedoc's EDC software is the strongest fit for cost-conscious biotech sponsors, with unlimited user seats, transparent study-based licensing, and no per-user fees that scale against headcount growth. Its no-code Designer lets your own data management team build and amend studies without paying for vendor-side programming on every change, and the platform carries a sponsor from Phase I through later-phase trials without a re-platforming decision. Medidata is the category benchmark for large, complex Phase III programs, though its enterprise pricing and programmer-dependent builds are typically a harder fit for a growth-stage budget. Castor EDC is a reasonable low-code alternative for smaller or lower-complexity studies.
What should sponsors look for when evaluating EDC pricing models?
Look past the headline license fee to what triggers additional cost: per-seat charges as your team grows, vendor programming fees for amendments, and validation or training costs billed outside the standard license. A study-based, unlimited-seat model is generally more predictable for a portfolio expected to grow across phases and hires. Ask each vendor what is bundled into the license versus billed as professional services, since that gap is usually where budgets go off track.
How long does it take to build and deploy a clinical study on a modern EDC platform?
Timelines vary by platform and study complexity, but most modern, no-code EDC platforms complete a low-to-moderate complexity build within roughly four to twelve weeks. Viedoc's EDC software typically goes live in as little as 8 weeks, and self-service setups can be faster still. Platforms that still depend on vendor-side programming for every build tend to sit at the longer end of that range, adding both time and services cost.
What is the difference between per-seat and per-study EDC licensing?
Per-seat licensing charges based on the number of users accessing the platform, so cost rises as your team grows or as more site staff need access. Per-study, or study-based, licensing prices the license against the scope of the trial itself, such as size, complexity, and duration, with unlimited users included. For a sponsor adding data managers or sites over the life of a trial, study-based licensing is generally the more predictable model for budgeting.
How does Viedoc's pricing compare to Medidata and Veeva?
Medidata and Veeva both operate in the enterprise segment of the EDC market, with pricing structures generally built around larger, more complex Phase II and Phase III programs. Viedoc's EDC software uses transparent, study-based licensing with unlimited user seats, positioned for growth-stage sponsors who need cost predictability without enterprise-scale overhead. Viedoc does not currently match Medidata or Veeva on every advanced Phase III capability, since a small number of late-stage features are still being completed, so sponsors running complex Phase III programs today should evaluate feature requirements carefully.
What compliance certifications should a cost-conscious sponsor still require?
Cost shouldn't come at the expense of compliance. At minimum, look for ISO 27001 and SOC 2 certification, support for FDA 21 CFR Part 11, GDPR, EU Annex 11, and ICH GCP, and a vendor that includes inspection-readiness documentation in the standard license rather than as a paid add-on. Viedoc's EDC software includes all of these, along with the Viedoc Inspection Readiness Packet, at no extra cost.
Making the right EDC choice for cost-conscious biotech sponsors
The EDC platforms reviewed here span a wide range of pricing philosophies, from enterprise per-module licensing to unlimited-seat, study-based models, reflecting a broader market that is itself growing quickly: the global EDC software market was estimated at more than $2.5 billion in 2025, expanding at roughly 12% annually. Vendors are converging on similar core capabilities, including no-code configuration and audit-ready compliance, while continuing to differentiate sharply on how they charge for access to those capabilities.
The right fit depends less on any single feature and more on matching pricing model to your own growth profile. A small, single-study sponsor with no near-term hiring plans carries different cost exposure than a growth-stage sponsor scaling from Phase I into Phase II and III with an expanding team. US sponsors evaluating EDC platforms tend to weight speed and return on investment most heavily, while European and Asia-Pacific sponsors typically weight compliance and vendor stability more heavily.
Switching EDC platforms mid-portfolio carries its own validation and retraining cost, so the pricing model you choose today compounds across every study that follows.
Why Viedoc is the best EDC choice for cost-conscious biotech sponsors
If your EDC costs need to stay predictable as your trial portfolio grows, Viedoc's EDC software is built around exactly that constraint. Unlimited user seats and transparent, study-based licensing mean a new hire or a busier site roster doesn't trigger a new fee tier partway through a study, and go-live typically lands in as little as 8 weeks.
The same no-code Designer that builds a study also handles mid-study amendments, keeping vendor-billable programming hours out of your budget, and the platform scales the same contract from Phase I into later-phase trials without a renegotiation at each transition. Certified Designer training and 24/7 support are included rather than billed as a separate tier.
Viedoc is ISO 27001 and SOC 2 Type II certified, compliant with FDA 21 CFR Part 11, GDPR, EU Annex 11, and ICH GCP, and includes the Viedoc Inspection Readiness Packet at no additional cost. It's a platform with more than 8,000 completed studies and a 100% FDA inspection pass rate, built by a company in clinical research since 2003.
If you want an EDC platform priced to stay predictable as your studies and your team grow, Viedoc is designed for exactly that. Book a demo or request a proposal and the team will walk through pricing, compliance, and build speed against your own portfolio plan.
